Abzena Hosts Second Biopharmaceutical Discovery and Development Symposium in Cambridge, UK on 19th February 2020
Abzena, the global biologics target-to-GMP Partner Research Organisation today announces it is hosting the second Biopharmaceutical Discovery and Development Symposium at the Babraham Research Campus in Cambridge on 19th February 2020.
The Symposium will highlight the latest technologies and advancements in the biopharmaceutical discovery and development field by Abzena and its partners, and how these have been successfully used by drug developers to create biopharmaceuticals to address significant unmet medical needs. External speakers currently announced include representatives from Iontas, UCL and Debiopharm.
There will also be the rare chance to tour of state-of-the-art laboratories used in discovery, immunology, bioassays, protein engineering, bioconjugation, bioanalytics and cell line development to showcase the contribution of these scientific groups to the biopharmaceutical discovery and development process.
Registration is free but attendees need register in advance at: https://abzena.com/development-services/open-day/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191215005015/en/
Contact information
Joseph Reeds
Marketing Manager, Abzena
Direct: +44 1223 903367
Office: +44 1223 903498
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KCAS Bio Strengthens Board of Directors with Appointment of Paul Kirchgraber and Kurt Doyle3.11.2025 10:30:00 EET | Press release
KCAS Bio, a leading contract research organization (CRO) specializing in comprehensive bioanalytical and biomarker services, is delighted to announce the appointment of Dr. Paul Kirchgraber and Mr. Kurt Doyle to its Board of Directors. Their addition marks a significant milestone in KCAS Bio’s continued growth and strategic evolution in the global life sciences industry. KCAS Bio is headquartered in the Kansas City, Kansas metropolitan area with operating sites in the greater Philadelphia area; Lyon, France; and a partnership in Melbourne, Australia. The Company is backed by Vitruvian Partners, one of the world’s leading growth-focused investment firms. Dr. Paul Kirchgraber brings decades of leadership experience in clinical research and laboratory operations. He served as Executive Vice President and CEO of Covance, Labcorp’s Drug Development Division, where he led global teams in drug and medical device development in over 60 countries. Dr. Kirchgraber has experience running global p
Eric Jing: Ant Group to Strengthen Support for Hong Kong's Global Finance and Tech Leadership with AI, GoGlobal Services3.11.2025 10:19:00 EET | Press release
Eric Jing, Chairman of Ant Group, reaffirmed Ant’s commitment to deepening cross-sector collaboration on regulated AI and tokenization innovation in the territory, and to expanding its cross-border payment and trade financing services to support Hong Kong’s initiative to help Chinese businesses go global. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251102787084/en/ John Lee, Chief Executive of Hong Kong SAR visited the booths of Ant International and Ant Digital Technologies during the 10th annual Hong Kong Fintech Week on November 3, 2025. Speaking on a panel with Christopher Hui, Hong Kong’s Secretary for Financial Services and the Treasury, and Fred Hu, Founder, Chairman and CEO of Primavera Capital Group at the 10th annual Hong Kong Fintech Week on November 3, 2025, Jing said the City’s visionary and prudent approach to policy innovation, rich commercial and financial use cases and a robust ecosystem of cross-sector c
SPM International Launches SPM Academy Inc. – a New Global Center for ISO-Compliant Vibration Training and Certification3.11.2025 10:00:00 EET | Press release
SPM Instrument, a global leader in condition monitoring, is taking the next step in its mission to empower industries with knowledge and tools that ensure reliability and performance. SPM Academy Inc., based in the U.S., will serve as a worldwide hub for vibration training and certification, strengthening industrial reliability expertise across sectors. Led by Bill Partipilo, CEO of SPM Instrument North America, the Academy builds on SPM’s long tradition of innovation and customer support through learning. “Our new global training center gives maintenance and reliability professionals the chance to develop their skills through interactive, high-quality course materials – in their local language, on a platform or location that suits them,” said Partipilo. SPM Academy combines practical exercises, simulators, and real-world case studies for a dynamic learning experience. Training and certification follow ISO/IEC 17024, ISO 18436-1, and ISO 18436-2. The SPM Academy Certification Center is
Kyowa Kirin International Announces Appointment of Julie Dehaene-Puype as President for the Region3.11.2025 10:00:00 EET | Press release
Kyowa Kirin International (“KKI”), a group company of Kyowa Kirin Co., Ltd. (TSE:4151, “Kyowa Kirin”), a Japan-based Global Specialty Pharmaceutical Company, today announced the appointment of Julie Dehaene-Puype as President for the Region, effective 1 November 2025. Julie follows the tenure of Jeremy Morgan, who has served as President for the International Region since 2023. Morgan will serve in an advisor role to the business through to the end of 2025, working in partnership with Dehaene-Puype to ensure a successful and smooth change for the company. “We are very pleased to welcome Julie to the company in the role as President of KKI,” said Tomohiro Sudo, Chief International Business Officer of Kyowa Kirin. “Julie joins us with extensive experience in global biotech and pharma spanning a 25-year career. I am confident that her expertise and her strong passion and care for people and patients will significantly contribute to KKI’s future growth for patients’ smiles, and we are look
Xpansiv Announces Acquisition of Evident to Strengthen Global Renewable Energy Markets3.11.2025 09:00:00 EET | Press release
Xpansiv® Limited (“Xpansiv”) and Evident Group Limited (“Evident”) today announced an agreement uniting their complementary registry and infrastructure capabilities to support the continued growth of the global renewable energy markets. The agreement, in which Xpansiv has wholly acquired Evident, follows an earlier, minority investment by Xpansiv in the registry operator and certification body. It combines Evident's international renewable energy for electricity “I-REC(E)” and other registries with Xpansiv’s North American Renewables Registry (NAR™) and Tradable Instrument for Global Renewables Registry (TIGR™) to establish a preeminent, global REC network with over 300 GW of capacity and more than 4,000 participating companies. “Today’s announcement reflects the shared goals and close relationship we have developed with Evident as we work to build energy transition solutions at scale, centering on transparent, independent certification and robust infrastructure,” said John Melby, CEO,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom